Clinical trials recruiting for Bladder cancer
59
Recruiting trials
44
US states with sites
22
Countries
7%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| 18F-FDG | 1 |
| CAdVEC | 1 |
| CLSP-1025 | 1 |
| CP-383 | 1 |
| Cemiplimab | 1 |
| Concurrent Radiation Therapy | 1 |
| Cytogenetics/ FISH | 1 |
| EBNK-001 + IL-15 + Pembrolizumab | 1 |
| EVOLVE104 | 1 |
| Functional tests | 1 |
| HER3-DXd | 1 |
| IDE397 | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Texas | 17 |
| California | 13 |
| Florida | 11 |
| New York | 11 |
| Maryland | 9 |
| Pennsylvania | 9 |
| Tennessee | 9 |
| Missouri | 8 |
| Ohio | 8 |
| North Carolina | 7 |
| Colorado | 6 |
| Illinois | 6 |
Top cities
Houston, Texas 13Nashville, Tennessee 9New York, New York 9Duarte, California 7Philadelphia, Pennsylvania 7St Louis, Missouri 7Los Angeles, California 6Dallas, Texas 5Omaha, Nebraska 5Seattle, Washington 5
Self-screener
Recruiting trials
- 18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
- A Beta-only IL-2 ImmunoTherapY Study
- A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
- A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies
- A Novel Imaging Protocol in Use to Identify Lymph Nodes and Organs of Interest
- A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas
- A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
- A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation
- A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
- A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- A Study of MGC026 in Participants With Advanced Solid Tumors
- A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
- A Study of a Side Effects and Resource Navigation Program for People With Cancer
- A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
- Adaptive Radiotherapy for Genitourinary Cancers
- Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors
- CONFIRM: Magnetic Resonance Guided Radiation Therapy
- Cancer Loyalty Card Study 2 (CLOCS-2)
- Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
- Comparison Capsule Sparing Cystectomy and Radical Cystoprostatectomy in Men with Bladder Cancer
- DESTINY-PANTUMOUR04
- Development of Urologic Registry for Personalized Medicine in Patients With Urologic Malignant Diseases by Analyzing Microbiome
- Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA
- Development of an AI-Agent for Urological Disease Diagnosis and Treatment
- Diagnostic Efficacy and Dosimetry of MNPR-101-DFO*-89Zr in Patients With Solid Tumors
- Dose-Escalation of MNPR-101-PCTA-177Lu in Solid Tumors
- Dosing Physical Activity Among Older Cancer Survivors Who Experience Chronic Pain: a Micro-randomized Trial
- EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
- Evaluating Safety and Efficacy of Prostate-sparing Radical Cystectomy
- Evaluation for NCI Surgery Branch Clinical Research Protocols
- Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
- Ex VIvo DEtermiNed Cancer Therapy
- Feasibility Study to Investigate Rectal Mucus in Aero-Digestive Tract Cancer.
- Feasibility of CBCT-Guided Online Adaptive Radiotherapy (FASCINATE)
- IDOV-Immune for Advanced Solid Tumors
- INTEGRATIVE "MULTI-OMICS" AND FUNCTIONAL PLATFORM FOR THE COMPLETE DIAGNOSTIC CHARACTERIZATION OF TUMORS: THE ITALIAN TUMOR CHEMOGENOMIC PROFILER (IT-TCP)
- Improving Care for Rural Patients With Solid Tumors
- Integrated Cancer Repository for Cancer Research
- Irreversible Electroporation (IRE) for Treating Recurrent Pelvic Tumors (PELFIRE Study)
- Occupational Situation and Return to Work of Urological Patients
- Online Adaptive Radiotherapy Using a Novel Linear Accelerator (ETHOS)
- Ovarian-Sparing Adaptive Radiotherapy in Young Adult Women
- PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
- Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients
- Prospective Evaluation of Cornerstone Robotics Sentire Surgical System in Major Gastrointestinal and Urologic Surgery
- Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors
- SL-28 for Advanced Solid Tumours
- SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
- Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
- Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
- Telehealth Intervention for Ostomy Self-Management
- The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
- The Man Van Project
- The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)
- Trop2-targeted immunoPET Imaging of Solid Tumors
- cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Related conditions
Trials recruiting for Bladder cancer often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Prostate cancer 1234Colorectal cancer 1359Pancreatic cancer 870Breast cancer 2239Melanoma 487Ovarian cancer 118Esophageal cancer 65Gastric cancer 91Head and neck cancer 62
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Bladder cancer trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.